D-LA3IK

D-LA3IK is a D-enantiomer peptide inhibitor designed to disrupt the Epidermal Growth Factor (EGF) signaling pathway, specifically targeting the biphasic oncogenic transcriptional reprogramming observed in prostate cancer. Developed as a more proteolytically stable version of the L-peptide LA3IK, it targets Annexin A2 (ANXA2) to suppress the activation of immediate-early genes (such as FOS, JUN, and the EGR family) and secondary phase processes including cell cycle progression, DNA replication, and the PI3K-AKT-mTOR and MAPK signaling axes. In preclinical models using PC3 prostate cancer cells, D-LA3IK demonstrated superior efficacy compared to its L-isomer in reversing EGF-induced transcriptomic changes and inhibiting tumor cell growth and survival, making it a potent candidate for disrupting oncogenic signaling in advanced prostate cancer.

Other names

D-LA3IK peptideD-LA-3IK peptideD-LA 3IK peptideD-enantiomer of LA3IKD-isomer of LA3IK